Novartis Ag

Irm LLC

Other

Glaxosmithkline Biologicals Sa

Alex Cortez

Xiaoyue Zhang

Yongkai Li

Tom Yao-Hsiang Wu

Timothy Z Hoffman

Manmohan Singh

Yefen Zou

Kathy Yue

Nicholas M Valiante

David Skibinski

Jianfeng Pan

Pranab Mishra

Tom Yao Hsiang Wu

Tetsuo Uno

Xing Wang

Shailaja Kasibhatla

Bernhard Hubert Geierstanger

David A G Skibinksi

David A G Skibinski

David Ag Skibinski

Timothy Hoffman

Nicholas Valiante

Provided herein are antibody conjugates comprising toll-like receptor agonists and the use of such conjugates for the treatment of cancer. In some embodiments, the conjugates comprise anti-HER2 antibodies.

Antibody conjugates comprising toll-like receptor agonist

The invention provides compounds of Formula (I), immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity. 

Compounds and compositions as toll-like receptor 7 agonists

Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminum salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.

Adsorption of immunopotentiators to insoluble metal salts

The invention provides a compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.

The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 7. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.

Compounds and compositions as TLR activity modulators

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: Xis N; Xis N Or CR; Xis &#x2014;CR&#x2550;CR. 

Growing community of inventors

San Diego, CA, United States of America

Alex Cortez